MDWD News and Press, MediWound Ltd. From 02/17/26

MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present ...

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx ® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabeti...

MediWound Reports New Clinical Data Demonstrating NexoBrid ® ’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid ® removes embedded particles in friction and blast wounds, reduc...

2025-11-21 06:15:08 ET H.C. Wainwright analyst issues BUY recommendation for MDWD on November 21, 2025 11:06AM ET. The previous analyst recommendation was Buy. MDWD was trading at $16.86 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

2025-11-20 10:43:26 ET MediWound Ltd. (MDWD) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy & Corporat...

2025-11-20 07:07:45 ET More on MediWound MediWound Is A Buy Opportunity On The Dip MediWound Q3 2025 Earnings Preview MediWound announces $30 million registered direct offering; shares down over 7% Seeking Alpha’s Quant Rating on MediWound Hist...

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equi...

Walmart Inc. (WMT) is expected to report $0.61 for Q3 2026 ATRenew Inc. American Depositary Shares (every three of which representing two Class A) (RERE) is expected to report $0.05 for Q3 2025 New Fortress Energy Inc. (NFE) is expected to report $-0.89 for Q3 2025 Maximus Inc. (MMS) ...

2025-11-19 09:53:08 ET More on MediWound MediWound Is A Buy Opportunity On The Dip MediWound announces $30 million registered direct offering; shares down over 7% Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWound ...

MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation e...